Drug Type Therapeutic vaccine, Dendritic cell vaccine |
Synonyms Cytotoxic T-cell therapy, Dendritic cell therapy, MASCT I + [6] |
Target- |
Action stimulants |
Mechanism Cytotoxic T lymphocytes stimulants, Immunologic cytotoxicity, Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Desmoplastic Small Round Cell Tumor | Phase 2 | China | 21 Feb 2024 | |
| Endometrial Stromal Sarcoma | Phase 2 | China | 21 Feb 2024 | |
| Hemangiosarcoma | Phase 2 | China | 21 Feb 2024 | |
| Leiomyosarcoma | Phase 2 | China | 21 Feb 2024 | |
| Liposarcoma | Phase 2 | China | 21 Feb 2024 | |
| Locally Advanced Soft Tissue Sarcoma | Phase 2 | China | 21 Feb 2024 | |
| Malignant Fibrous Histiocytoma | Phase 2 | China | 21 Feb 2024 | |
| Neurofibrosarcoma | Phase 2 | China | 21 Feb 2024 | |
| Rhabdomyosarcoma | Phase 2 | China | 21 Feb 2024 | |
| Soft Tissue Sarcoma | Phase 2 | China | 21 Feb 2024 |
Phase 1 | 39 | aypnuecnuu(gsbgvjeixa) = bhmvvrpcvt modpxowcqo (unwersrlgn ) View more | Positive | 24 May 2024 | |||
MASCT-I plus camrelizumab | kcrfxotihr(drdqkekwsk) = awhtbxwxiw pmtwrgspri (qsxtcsgthr ) View more | ||||||
Phase 1 | Osteosarcoma First line | 19 | nzwehllamu(jokrwbccvr) = 11 (57.9%) experienced grade 3 or 4 treatment-related adverse events emhpwafnqm (qtvmolrqli ) | Positive | 29 Nov 2023 | ||
Phase 1 | 39 | irfzadjbmd(utfwkchztt) = vagigfjttm vkkamwkohs (ikonsdatfb ) View more | Positive | 26 May 2023 | |||
Phase 2 | 10 | zqowdatlnn(rgpujitwdt) = rvlxecacwp alncoinhsw (twzkprfprs ) View more | Positive | 03 Jun 2022 | |||
Phase 1 | Advanced gastric carcinoma PD-L1 expression | microsatellite instability | 15 | cortemhkga(rcvsachadn) = Abnormal liver function may be related to Camrelizumab qgylpjbgmt (cxpznhoash ) View more | - | 22 Jan 2021 | ||
Phase 1/2 | 70 | hyijguyajk(mcjzlxwnmk) = pxmbktfomh neqttwkdzi (bggqympvwj ) View more | Positive | 01 Sep 2019 | |||
hyijguyajk(mcjzlxwnmk) = upgtrhszap neqttwkdzi (bggqympvwj ) View more | |||||||
Phase 1/2 | Advanced Malignant Solid Neoplasm PD-1 | VEGF | VEGF receptor 2 | - | PD-1 blockade-activated MASCT alone | ahhyjrhduw(usolggjjai) = rvcjxktmqp gngdyirzoq (kfevozkdeg ) View more | Positive | 26 May 2019 | |
PD-1 blockade-activated MASCT plus apatinib | ahhyjrhduw(usolggjjai) = zmbuvehdwx gngdyirzoq (kfevozkdeg ) View more |





